GlassScriptPhysician profile
Sood Kisra
NPI 1619243805
$3,728.49
in general payments reported to CMS, 2019-2025
22 companies · $670 in 2025
The $670 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $633 · 2021: $678 · 2022: $484 · 2023: $300 · 2024: $361 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,314.73 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $628.38 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $551.32 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $493.70 | 2019-2025 | Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $381.16 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| Pfizer INC. | $345.26 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $305.66 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $273.85 | 2023-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.79 | 2020-2022 | |
| Amgen INC. | $181.48 | 2021-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $67.74 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $63.26 | 2019-2023 | Eliquis |
| Medtronic Vascular, INC. | $46.40 | 2019-2020 | |
| Irhythm Technologies, INC. | $32.23 | 2023 | Zio Xt Patch |
| Amarin Pharma, INC. | $24.04 | 2020 | |
| Abiomed | $23.76 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $21.18 | 2025 | |
| Abbott Laboratories | $20.00 | 2025 | Jot Dx |
| Masimo Corporation | $18.75 | 2023 | Na |
| Digirad Health, INC | $18.16 | 2023 | Cardius |
| Boston Scientific Corporation | $17.02 | 2022 | |
| Bardy Diagnostics, INC. | $16.98 | 2022 | |
| Glaxosmithkline, LLC. | $16.37 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sood Kisra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.